Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy
LC Hartmann, KH Lu, GP Linette, WA Cliby, KR Kalli… - Clinical cancer …, 2005 - AACR
LC Hartmann, KH Lu, GP Linette, WA Cliby, KR Kalli, D Gershenson, RC Bast, J Stec…
Clinical cancer research, 2005•AACRPurpose: Women with advanced epithelial ovarian cancer are routinely treated with platinum-
paclitaxel chemotherapy following cytoreductive surgery, yet only∼ 20% achieve long-term
disease-free survival. We hypothesized that differences in gene expression before treatment
could distinguish patients with short versus long time to recurrence after administration of
platinum-paclitaxel combination chemotherapy. Experimental Design: To test this
hypothesis, gene expression profiling of 79 primary surgically resected tumors from women …
paclitaxel chemotherapy following cytoreductive surgery, yet only∼ 20% achieve long-term
disease-free survival. We hypothesized that differences in gene expression before treatment
could distinguish patients with short versus long time to recurrence after administration of
platinum-paclitaxel combination chemotherapy. Experimental Design: To test this
hypothesis, gene expression profiling of 79 primary surgically resected tumors from women …
Abstract
Purpose: Women with advanced epithelial ovarian cancer are routinely treated with platinum-paclitaxel chemotherapy following cytoreductive surgery, yet only ∼20% achieve long-term disease-free survival. We hypothesized that differences in gene expression before treatment could distinguish patients with short versus long time to recurrence after administration of platinum-paclitaxel combination chemotherapy.
Experimental Design: To test this hypothesis, gene expression profiling of 79 primary surgically resected tumors from women with advanced-stage, high-grade epithelial ovarian cancer was done using cDNA microarrays containing 30,721 genes. Supervised learning algorithms were applied in an effort to develop a binary classifier that could discriminate women at risk for early (≤21 months) versus late (>21 months) relapse after initial chemotherapy.
Results: A 14-gene predictive model was developed using a set of training samples (n = 51) and subsequently tested using an independent set of test samples (n = 28). This model correctly predicted the outcome of 24 of the 28 test samples (86% accuracy) with 95% positive predictive value for early relapse.
Conclusions: Predictive markers for early recurrence can be identified for platinum-paclitaxel combination chemotherapy in primary ovarian carcinoma. The proposed 14-gene model requires further validation.
AACR